{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:40:16Z","timestamp":1764873616761,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The transmembrane zink-metalloendopeptidase neprilysin (NEP) is implicated in cardiovascular disease but also tumor biology. The aim of the study was to investigate the relationship of circulating NEP (cNEP) levels with established cardiovascular biomarkers and its effect on overall survival in an unselected cohort of treatment-na\u00efve cancer patients. 555 consecutive cancer patients prior anticancer therapy were enrolled prospectively. NEP levels were determined alongside routine laboratory parameters, established cardiac biomarkers, i.e. NT-proBNP, hsTnT, MR-proANP, MR-proADM, CT-proET-1 and Copeptin, and inflammatory parameters, i.e. CRP, IL-6 and SAA, in venous plasma samples. All-cause mortality was the primary endpoint. cNEP levels of 276\u2009pg\/ml (IQR: 0\u20135981) displayed a weak\u00a0inverse correlation with age [r\u2009=\u2009\u22120.12, p\u2009=\u20090.023] and inflammatory status [r\u2009=\u2009\u22120.14, p\u2009=\u20090.007 CRP; r\u2009=\u2009\u22120.20, p\u2009&lt;\u20090.001 IL-6 and r\u2009=\u2009\u22120.18, p\u2009&lt;\u20090.001 SAA]. cNEP was comparable between different tumor entities and stages and not related to functional parameters of other organ systems as kidney, liver or especially the heart. Moreover, cNEP was not associated with overall survival in the total cohort [adj.HR for ln (cNEP) 1.00, 95% CI: 0.94\u20131.06, p\u2009=\u20090.887] but in myelodysplatic malignancies [adj.HR for ln (cNEP) 1.27, 95% CI: 1.01\u20131.61, p\u2009=\u20090.044]. In conclusion, cNEP lacks association with outcome but for myelodysplastic disease. cNEP shows no correlation with established cardiovascular biomarkers related to prognosis, thereby holding a limited potential as a biomarker in cardio-oncology.<\/jats:p>","DOI":"10.1038\/s41598-019-38867-2","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T11:03:34Z","timestamp":1550833414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The circulating form of neprilysin is not a general biomarker for overall survival in treatment-na\u00efve cancer patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Noemi","family":"Pavo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrike","family":"Arfsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Goliasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp E.","family":"Bartko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3027-7775","authenticated-orcid":false,"given":"Raphael","family":"Wurm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Kornek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Strunk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-5802","authenticated-orcid":false,"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"H\u00fclsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"38867_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371, 993\u20131004, https:\/\/doi.org\/10.1056\/NEJMoa1409077 (2014).","journal-title":"N Engl J Med"},{"key":"38867_CR2","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37, 2129\u20132200, https:\/\/doi.org\/10.1093\/eurheartj\/ehw128 (2016).","journal-title":"Eur Heart J"},{"key":"38867_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ejhf.435","volume":"18","author":"G Goliasch","year":"2016","unstructured":"Goliasch, G. et al. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail 18, 89\u201393, https:\/\/doi.org\/10.1002\/ejhf.435 (2016).","journal-title":"Eur J Heart Fail"},{"key":"38867_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jacc.2014.11.048","volume":"65","author":"A Bayes-Genis","year":"2015","unstructured":"Bayes-Genis, A. et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 65, 657\u2013665, https:\/\/doi.org\/10.1016\/j.jacc.2014.11.048 (2015).","journal-title":"J Am Coll Cardiol"},{"key":"38867_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ejhf.654","volume":"19","author":"JL Zamorano","year":"2017","unstructured":"Zamorano, J. L. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19, 9\u201342, https:\/\/doi.org\/10.1002\/ejhf.654 (2017).","journal-title":"Eur J Heart Fail"},{"key":"38867_CR6","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","volume":"101","author":"N Pavo","year":"2015","unstructured":"Pavo, N. et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 101, 1874\u20131880, https:\/\/doi.org\/10.1136\/heartjnl-2015-307848 (2015).","journal-title":"Heart"},{"key":"38867_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/stem.592","volume":"29","author":"V Maguer-Satta","year":"2011","unstructured":"Maguer-Satta, V., Besancon, R. & Bachelard-Cascales, E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells 29, 389\u2013396, https:\/\/doi.org\/10.1002\/stem.592 (2011).","journal-title":"Stem Cells"},{"key":"38867_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","volume":"14","author":"DJ Campbell","year":"2017","unstructured":"Campbell, D. J. Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol 14, 171\u2013186, https:\/\/doi.org\/10.1038\/nrcardio.2016.200 (2017).","journal-title":"Nat Rev Cardiol"},{"key":"38867_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/NEN.0b013e3182345e46","volume":"70","author":"JS Miners","year":"2011","unstructured":"Miners, J. S., Barua, N., Kehoe, P. G., Gill, S. & Love, S. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70, 944\u2013959, https:\/\/doi.org\/10.1097\/NEN.0b013e3182345e46 (2011).","journal-title":"J Neuropathol Exp Neurol"},{"key":"38867_CR10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.V78.7.1834.1834","volume":"78","author":"MA Shipp","year":"1991","unstructured":"Shipp, M. A., Stefano, G. B., Switzer, S. N., Griffin, J. D. & Reinherz, E. L. CD10 (CALLA)\/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood 78, 1834\u20131841 (1991).","journal-title":"Blood"},{"key":"38867_CR11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood.V54.6.1240.1240","volume":"54","author":"JM Pesando","year":"1979","unstructured":"Pesando, J. M. et al. Leukemia-associated antigens in ALL. Blood 54, 1240\u20131248 (1979).","journal-title":"Blood"},{"key":"38867_CR12","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","volume":"15","author":"WW Choi","year":"2009","unstructured":"Choi, W. W. et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15, 5494\u20135502, https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0113 (2009).","journal-title":"Clin Cancer Res"},{"key":"38867_CR13","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1182\/blood-2007-11-120535","volume":"111","author":"FE Craig","year":"2008","unstructured":"Craig, F. E. & Foon, K. A. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111, 3941\u20133967, https:\/\/doi.org\/10.1182\/blood-2007-11-120535 (2008).","journal-title":"Blood"},{"key":"38867_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-40","volume":"14","author":"K Leithner","year":"2014","unstructured":"Leithner, K. et al. Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells. BMC Cancer 14, 40, https:\/\/doi.org\/10.1186\/1471-2407-14-40 (2014).","journal-title":"BMC Cancer"},{"key":"38867_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.lungcan.2015.06.003","volume":"89","author":"K Kadota","year":"2015","unstructured":"Kadota, K. et al. Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. Lung Cancer 89, 329\u2013336, https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.003 (2015).","journal-title":"Lung Cancer"},{"key":"38867_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10549-007-9516-9","volume":"106","author":"M Smollich","year":"2007","unstructured":"Smollich, M. et al. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat 106, 361\u2013369, https:\/\/doi.org\/10.1007\/s10549-007-9516-9 (2007).","journal-title":"Breast Cancer Res Treat"},{"key":"38867_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.16","volume":"5","author":"HM Stephen","year":"2016","unstructured":"Stephen, H. M. et al. Epigenetic suppression of neprilysin regulates breast cancer invasion. Oncogenesis 5, e207, https:\/\/doi.org\/10.1038\/oncsis.2016.16 (2016).","journal-title":"Oncogenesis"},{"key":"38867_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/gut.2009.178376","volume":"59","author":"H Kuniyasu","year":"2010","unstructured":"Kuniyasu, H. et al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut 59, 348\u2013356, https:\/\/doi.org\/10.1136\/gut.2009.178376 (2010).","journal-title":"Gut"},{"key":"38867_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000087476","volume":"69","author":"M Terauchi","year":"2005","unstructured":"Terauchi, M. et al. Anti-progressive effect of neutral endopeptidase 24.11 (NEP\/CD10) on cervical carcinoma in vitro and in vivo. Oncology 69, 52\u201362, https:\/\/doi.org\/10.1159\/000087476 (2005).","journal-title":"Oncology"},{"key":"38867_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000093901","volume":"77","author":"S Bircan","year":"2006","unstructured":"Bircan, S. et al. CD10 expression in urothelial bladder carcinomas: a pilot study. Urol Int 77, 107\u2013113, https:\/\/doi.org\/10.1159\/000093901 (2006).","journal-title":"Urol Int"},{"key":"38867_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00008390-200206000-00007","volume":"12","author":"J Kanitakis","year":"2002","unstructured":"Kanitakis, J., Narvaez, D. & Claudy, A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 12, 241\u2013244 (2002).","journal-title":"Melanoma Res"},{"key":"38867_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1746-1596-4-38","volume":"4","author":"B Bahadir","year":"2009","unstructured":"Bahadir, B., Behzatoglu, K., Bektas, S., Bozkurt, E. R. & Ozdamar, S. O. CD10 expression in urothelial carcinoma of the bladder. Diagn Pathol 4, 38, https:\/\/doi.org\/10.1186\/1746-1596-4-38 (2009).","journal-title":"Diagn Pathol"},{"key":"38867_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000325951","volume":"50","author":"L Wang","year":"2006","unstructured":"Wang, L., Vuolo, M., Suhrland, M. J. & Schlesinger, K. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol 50, 257\u2013262 (2006).","journal-title":"Acta Cytol"},{"key":"38867_CR24","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1164\/arrd.1985.132.6.1262","volume":"132","author":"AR Johnson","year":"1985","unstructured":"Johnson, A. R., Coalson, J. J., Ashton, J., Larumbide, M. & Erdos, E. G. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme. Am Rev Respir Dis 132, 1262\u20131267, https:\/\/doi.org\/10.1164\/arrd.1985.132.6.1262 (1985).","journal-title":"Am Rev Respir Dis"},{"key":"38867_CR25","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/0006-2952(90)90012-A","volume":"39","author":"MG Spillantini","year":"1990","unstructured":"Spillantini, M. G., Sicuteri, F., Salmon, S. & Malfroy, B. Characterization of endopeptidase 3.4.24.11 (\u201cenkephalinase\u201d) activity in human plasma and cerebrospinal fluid. Biochem Pharmacol 39, 1353\u20131356 (1990).","journal-title":"Biochem Pharmacol"},{"key":"38867_CR26","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/clinchem\/38.9.1785","volume":"38","author":"T Yandle","year":"1992","unstructured":"Yandle, T. et al. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem 38, 1785\u20131791 (1992).","journal-title":"Clin Chem"},{"key":"38867_CR27","first-page":"87","volume":"45","author":"BP Roques","year":"1993","unstructured":"Roques, B. P., Noble, F., Dauge, V., Fournie-Zaluski, M. C. & Beaumont, A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45, 87\u2013146 (1993).","journal-title":"Pharmacol Rev"},{"key":"38867_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbrc.2014.01.158","volume":"446","author":"S Kuruppu","year":"2014","unstructured":"Kuruppu, S., Rajapakse, N. W., Minond, D. & Smith, A. I. Production of soluble Neprilysin by endothelial cells. Biochem Biophys Res Commun 446, 423\u2013427, https:\/\/doi.org\/10.1016\/j.bbrc.2014.01.158 (2014).","journal-title":"Biochem Biophys Res Commun"},{"key":"38867_CR29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/ijo.2010.227","volume":"35","author":"KF Standeven","year":"2011","unstructured":"Standeven, K. F. et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 35, 1031\u20131040, https:\/\/doi.org\/10.1038\/ijo.2010.227 (2011).","journal-title":"Int J Obes (Lond)"},{"key":"38867_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jchf.2015.03.011","volume":"3","author":"N Vodovar","year":"2015","unstructured":"Vodovar, N. et al. Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. JACC Heart Fail 3, 629\u2013636, https:\/\/doi.org\/10.1016\/j.jchf.2015.03.011 (2015).","journal-title":"JACC Heart Fail"},{"key":"38867_CR31","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/eurheartj\/ehx679","volume":"39","author":"M Arrigo","year":"2018","unstructured":"Arrigo, M. et al. The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin. Eur Heart J 39, 1794\u20131798, https:\/\/doi.org\/10.1093\/eurheartj\/ehx679 (2018).","journal-title":"Eur Heart J"},{"key":"38867_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy066","author":"IE Emrich","year":"2018","unstructured":"Emrich, I. E. et al. Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients? Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfy066 (2018).","journal-title":"Nephrol Dial Transplant"},{"key":"38867_CR33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1750-3639.2010.00375.x","volume":"20","author":"JS Miners","year":"2010","unstructured":"Miners, J. S., van Helmond, Z., Kehoe, P. G. & Love, S. Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol 20, 794\u2013802, https:\/\/doi.org\/10.1111\/j.1750-3639.2010.00375.x (2010).","journal-title":"Brain Pathol"},{"key":"38867_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","volume":"68","author":"A Bayes-Genis","year":"2016","unstructured":"Bayes-Genis, A., Barallat, J. & Richards, A. M. A Test in Context: Neprilysin: Function, Inhibition, and Biomarker. J Am Coll Cardiol 68, 639\u2013653, https:\/\/doi.org\/10.1016\/j.jacc.2016.04.060 (2016).","journal-title":"J Am Coll Cardiol"},{"key":"38867_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0090-1229(75)90041-0","volume":"4","author":"MF Greaves","year":"1975","unstructured":"Greaves, M. F., Brown, G., Rapson, N. T. & Lister, T. A. Antisera to acute lymphoblastic leukemia cells. Clin Immunol Immunopathol 4, 67\u201384 (1975).","journal-title":"Clin Immunol Immunopathol"},{"key":"38867_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/modpathol.3800713","volume":"20","author":"NA Makretsov","year":"2007","unstructured":"Makretsov, N. A. et al. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 20, 84\u201389, https:\/\/doi.org\/10.1038\/modpathol.3800713 (2007).","journal-title":"Mod Pathol"},{"key":"38867_CR37","first-page":"525","volume":"17","author":"Y Ohji","year":"2007","unstructured":"Ohji, Y. et al. Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: multivariate analysis of clinicopathological and immunohistochemical factors. Oncol Rep 17, 525\u2013530 (2007).","journal-title":"Oncol Rep"},{"key":"38867_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.healun.2015.12.015","volume":"35","author":"A Bayes-Genis","year":"2016","unstructured":"Bayes-Genis, A., Prickett, T. C., Richards, A. M., Barallat, J. & Lupon, J. Soluble neprilysin retains catalytic activity in heart failure. J Heart Lung Transplant 35, 684\u2013685, https:\/\/doi.org\/10.1016\/j.healun.2015.12.015 (2016).","journal-title":"J Heart Lung Transplant"},{"key":"38867_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/00003246-199903000-00034","volume":"27","author":"A Martens","year":"1999","unstructured":"Martens, A., Eppink, G. J., Woittiez, A. J., Eidhof, H. & de Leij, L. F. Neutrophil function capacity to express CD10 is decreased in patients with septic shock. Crit Care Med 27, 549\u2013553 (1999).","journal-title":"Crit Care Med"},{"key":"38867_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/cc8872","volume":"14","author":"C Pierrakos","year":"2010","unstructured":"Pierrakos, C. & Vincent, J. L. Sepsis biomarkers: a review. Crit Care 14, R15, https:\/\/doi.org\/10.1186\/cc8872 (2010).","journal-title":"Crit Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38867-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38867-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38867-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T06:28:56Z","timestamp":1671258536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38867-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["38867"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-38867-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"8 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2554"}}